Completed
A Multicenter, Double-Blind, Randomized Comparison Study Of the Efficacy and Safety of Tigecycline to Imipenem/ Cilastatin to Treat Complicated Intra-Abdominal Infections in Hospitalized Subjects
What is being tested
Tigecycline
Drug
Who is being recruted
Bacterial Infections and Mycoses+6
+ Iatrogenic Disease
+ Infections
Over 8 Years
+6 Eligibility Criteria
How is the trial designed
Treatment Study
Phase 3
Interventional
Study Start: November 2002
Summary
Principal SponsorWyeth is now a wholly owned subsidiary of Pfizer
Last updated: February 8, 2013
Sourced from a government-validated database.Claim as a partner
Study start date: November 1, 2002
Actual date on which the first participant was enrolled.Purpose: To provide a mechanism for the emergency use of tigecycline in the appropriate clinical situations.
Principal SponsorWyeth is now a wholly owned subsidiary of Pfizer
Last updated: February 8, 2013
Sourced from a government-validated database.Claim as a partner
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Design Details
850 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Conditions
Criteria
Any sex
Biological sex of participants that are eligible to enroll.Over 8 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Bacterial Infections and MycosesIatrogenic DiseaseInfectionsPathologic ProcessesPathological Conditions, Signs and SymptomsDisease AttributesBacterial InfectionsCross InfectionGram-Positive Bacterial Infections
Criteria
3 inclusion criteria required to participate
Male or female subjects, >= 8 years of age and a weight of >= 35 kilograms
Subjects who have failed or are intolerant of other available appropriate antibiotic therapies or whose pathogens are resistant to other available antibiotics
Subjects with selected culture-positive infections caused by a multiple antibiotic-resistant pathogen presumed to be susceptible to tigecycline
3 exclusion criteria prevent from participating
Known or suspected hypersensitivity to tigecycline, tetracyclines, or other compounds related to this class of antibacterial agents
Subjects who are moribund with an expected survival of less than 2 weeks
Subjects who have been designated as "Do Not Resuscitate", unless it is anticipated within a reasonable degree of medical certainty that they can achieve benefit from potentially curative antibiotic therapy
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has no location dataSave this study to your profile to know when the location data is available.
CompletedNo study centers